Midkine: a powerful indicator of early cancer
Extensively validated as a cancer biomarker, midkine has three distinct advantages over many current biomarkers used to manage disease:
- Midkine is elevated very early in disease- often well before any symptoms are apparent
- Midkine is elevated in many types of cancer, giving midkine broad diagnostic potential
- Midkine is readily detected in the blood and urine making biopsies unnecessary
Cellmid has developed a fully validated MK ELISA which accurately quantifies serum midkine levels. As well as selling this assay to the research community, Cellmid is using this assay in two in-house diagnostic programs for human and veterinary cancer.